Research programme: phosphodiesterase V inhibitors - Plexxikon

Drug Profile

Research programme: phosphodiesterase V inhibitors - Plexxikon

Alternative Names: Phosphodiesterase V inhibitors research programme - Plexxikon

Latest Information Update: 10 Mar 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Plexxikon
  • Class
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Erectile dysfunction

Most Recent Events

  • 10 Mar 2008 No development reported - Preclinical for Erectile dysfunction in USA (unspecified route)
  • 27 Feb 2004 Compounds from this programme are available for licensing (http://www.plexxikon.com/)
  • 27 Feb 2004 Preclinical trials in Erectile dysfunction in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top